158 completed, 62 terminated, 56 recruiting, 34 unknown. 365 Phase 2, 42 Phase 1, 39 Phase 3.
Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH). TRA16, Placebo - Enteric Hyperoxaluria | Phase 2 | Not yet recruiting | Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. | 30 | 2027-03-01 | 2026-10-13 |
| Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Nitazoxanide (NTZ) - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 44 | 2027-01-01 | 2026-09-15 |
| Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation Aquamin, Placebo - Ulcerative Colitis, Ileal Pouch | Phase 2 | Recruiting | Muhammad N Aslam, MD | 52 | 2026-11-01 | 2026-10-20 |
| Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis Oral Vancomycin - Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | Tampere University Hospital | 140 | 2026-10-01 | 2026-09-10 |
| A Study of AC-101 Tablets in Patients With Ulcerative Colitis AC-101, Placebo - Ulcerative Colitis (UC) | Phase 2 | Recruiting | Accro Bioscience (Suzhou) Limited | 153 | 2026-09-10 | 2026-10-28 |
| A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis PALI-2108, Placebo - Ulcerative Colitis (UC), Severe Ulcerative Colitis | Phase 2 | Recruiting | Palisade Bio | 204 | 2026-08-28 | 2026-10-21 |
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer Vedolizumab, Placebo - IrAE, Immune-related Adverse Event | Phase 2 / Phase 3 | Recruiting | AHS Cancer Control Alberta | 36 | 2026-08-13 | 2026-08-27 |
| Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) Modafinil, Placebo - Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Chronic Fatigue | Phase 2 / Phase 3 | Recruiting | Radboud University Medical Center | 60 | 2026-08-03 | 2026-09-14 |
| A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PTT-621 in Patients With Moderately to Severely Active Ulcerative Colitis PTT-621 Tablets - Ulcerative Colitis (UC) | Phase 2 | Not yet recruiting | Pyrotech Therapeutics, Inc. | 40 | 2026-08-01 | 2026-08-07 |
| Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative Colitis Low molecular weight fucoidan and standard care, Placebo and standard of care - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Enrolling by invitation | Allama Iqbal Medical College | 90 | 2026-08-01 | 2026-08-26 |
| Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis Risankizumab, Trosunilimab, ABBV-701 - Crohn's Disease, Ulcerative Colitis | Phase 2 | Recruiting | AbbVie | 2000 | 2026-07-31 | 2026-10-27 |
| Oral Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis Fecal Microbiota Transplantation by Stool capsules, Fecal Microbiota Transplantation by Intra-rectal enemas - Pediatric Ulcerative Colitis in Remission | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 26 | 2026-07-01 | 2026-05-06 |
| PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure methoxsalen, Extracorporeal photopheresis (ECP), Vedolizumab - Colitis, Hepatitis | Phase 2 | Not yet recruiting | Therakos LLC | 112 | 2026-07-01 | 2026-06-02 |
| Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Placebo (blinded), Vancomycin (blinded), Vancomycin (open-label extension) - Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Recruiting | McMaster University | 14 | 2026-06-17 | 2026-10-09 |
| A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis INT-210 Capsule - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Recruiting | Innatus Therapeutics (Shanghai) Co., Ltd. | 24 | 2026-06-11 | 2026-07-09 |
| Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD SPY001, SPY002, SPY003 - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 2 | Enrolling by invitation | Spyre Therapeutics, Inc. | 645 | 2026-06-08 | 2026-10-27 |
| A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis Etrasimod - Colitis, Ulcerative | Phase 2 | Recruiting | Pfizer | 24 | 2026-05-28 | 2026-10-26 |
| A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) balinatunfib, balinatunfib-matching placebo - Colitis Ulcerative, Crohn's Disease | Phase 2 | Terminated | Sanofi | 7 | 2026-05-19 | 2026-10-22 |
| A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089 - Colitis, Ulcerative, Crohn Disease | Phase 2 | Recruiting | Eli Lilly and Company | 60 | 2026-05-04 | 2026-10-22 |
| Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC) ATH-063, Placebo - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 2 | Recruiting | Athos Therapeutics Inc | 120 | 2026-04-30 | 2026-09-21 |
Showing 20 of 365. Sign in to see all of them.
Colitis, Ulcerative (344) · Inflammatory Bowel Diseases (77) · Crohn Disease (45) · Gastrointestinal Diseases (9) · Lymphoma, Follicular (7) · Ulcer (7) · Diarrhea (6) · Digestive System Diseases (6) · Intestinal Diseases (5) · Cholangitis, Sclerosing (4) · Colitis, Microscopic (4) · Colonic Diseases (4) · Fatigue (4) · Melanoma (4)
Gastroenteritis (363) · Colonic Diseases (361) · Intestinal Diseases (360) · Digestive System Diseases (359) · Gastrointestinal Diseases (356) · Inflammatory Bowel Diseases (271) · Pathological Conditions, Signs and Symptoms (31) · Pathologic Processes (19) · Signs and Symptoms (15) · Immune System Diseases (14) · Hemic and Lymphatic Diseases (13) · Neoplasms (12) · Neoplasms by Histologic Type (11) · Signs and Symptoms, Digestive (8)
Fecal Microbiota Transplantation (21) · Mesalamine (13) · vedolizumab (12) · etrasimod (7) · ABX464 (5) · Infliximab (5) · golimumab (5) · mirikizumab (5) · visilizumab (5) · Adalimumab (4) · Budesonide (4) · Methylprednisolone (4) · Vancomycin (4) · spesolimab (4) · Aquamin (3)
Pfizer (10) · Sanofi (9) · Janssen Research & Development, LLC (8) · AbbVie (7) · Bristol-Myers Squibb (6) · Eli Lilly and Company (6) · Facet Biotech (6) · Genentech, Inc. (6) · Abivax S.A. (5) · Boehringer Ingelheim (5) · GlaxoSmithKline (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Takeda (5) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (4) · Amgen (4)
United States (179) · Poland (115) · Germany (94) · Canada (91) · Hungary (85) · Italy (77) · Czechia (72) · France (72) · Belgium (71) · United Kingdom (62) · Ukraine (58) · Israel (55) · Netherlands (54) · Australia (52) · Spain (51)
Wolfgang Stremmel, Professor (3) · Arena CT.gov Administrator (2)
PMID 30721964, PMID 26893500, PMID 31982148, PMID 39778975, PMID 41359652, PMID 16984503, PMID 17222320, PMID 17920064, PMID 17975182, PMID 18325386, PMID 18623174, PMID 19145731, PMID 19714757, PMID 19885903, PMID 20048683, PMID 20413687, PMID 20947884, PMID 21453880, PMID 21471566, PMID 21871249, PMID 21929562, PMID 21991594, PMID 22549092, PMID 22605655, PMID 22894574, PMID 23078909, PMID 23188075, PMID 23461895, PMID 23648372, PMID 23714676, PMID 23735746, PMID 23846486, PMID 23872668, PMID 23909727, PMID 24558033, PMID 24796768, PMID 24814090, PMID 25185797, PMID 25192498, PMID 25304132, PMID 25567115, PMID 25651782, PMID 25836986, PMID 25857665, PMID 25996351, PMID 26070003, PMID 26119226, PMID 26363929, PMID 26376350, PMID 26478682
2023 (14), 2016 (10), 2017 (10), 2018 (10), 2025 (10), 2019 (5), 2014 (4), 2009 (2), 2015 (2), 2005 (1), 2008 (1), K23DK073750 (1), P30CA060553 (1), R01DK059961 (1), R01DK128257 (1)